Assessing the risk of birth defects from new antiviral drugs
Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models
This study is looking into whether new antiviral medications for COVID-19 could cause birth defects, using lab models to see how these drugs might affect early pregnancy, so doctors can better understand their safety for pregnant patients or those planning to become pregnant.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project ID | NIH-10741474 on NIH RePORTER |
What this research studies
This research investigates the potential risks of birth defects associated with new antiviral medications, particularly those developed for COVID-19. Using advanced 3D morphogenesis models derived from stem cells, the study aims to evaluate how these drugs may affect embryonic development. By simulating early embryogenesis in a lab setting, researchers can identify any teratogenic effects of these antiviral drugs at concentrations similar to those used in treatment. The findings will help inform healthcare providers about the safety of these medications for patients who are pregnant or may become pregnant.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals of childbearing potential who may require antiviral treatment for COVID-19.
Not a fit: Patients who are not pregnant or do not plan to become pregnant may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could provide critical information on the safety of antiviral drugs during pregnancy, potentially preventing birth defects.
How similar studies have performed: Previous studies using similar 3D morphogenesis models have shown promise in assessing teratogenic effects, indicating a potential for success in this novel application.
Where this research is happening
Honolulu, United States
- University of Hawaii at Manoa — Honolulu, United States (Active)
Researchers
- Principal investigator: Marikawa, Yusuke — University of Hawaii at Manoa
- Study coordinator: Marikawa, Yusuke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.